Cardiff University: 10 years to end cancer's resistance
The potential impact of a new cancer drug invented in Cardiff has been called "remarkable" at the world's biggest gathering of oncologists.
Designed to stop patients becoming resistant to common therapies, tests have shown Acelarin to be effective in tackling a range of different cancers.
The results of first and second phase clinical trials of the drug are being presented in Chicago.
The treatment was invented in laboratories at Cardiff University.
Prof Chris McGuigan describes a decade's work at the school of pharmacy on the new anti-cancer drug.
30 May 2015